Tag : ADVERSE EFFECTS

Baricitinib is a selective Janus kinase inhibitor approved in over 70 countries for treating moderate-to-severe atopic dermatitis (AD) in adults. In the European Union, Saudi Arabia, and Japan, it is also approved for children and adolescents aged 2 years and older with moderate-to-severe AD who are eligible for systemic therapy. Previous integrated analyses showed that baricitinib maintained a similar safety profile with no new safety signals, and the incidence of adverse events of special interest during long-term follow-up remained low.